Skip to main content
  • Government constitute Committee on affordable medicines and health products

    Government constitutes a committee on affordable medicines and health products to address the issues of pharma industries giving temptation for prescribing medicines.

    The committee is chaired by Niti ayog and contains five members which includes, Chief Economic Adviser, Ministry of Finance; Secretary, Department of Health Research; Vice-Chairperson, NLEM Joint; Secretary, Department of Industrial Policy & Promotion; and Director General of Health Services, Ministry of Health & Family Welfare.

  • Affordable Sitagliptin reaches rack of Janaushadhi Kendras

    Sitagliptin, a new variant of medicines for diabetes, launched at affordable prices for all under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. PMBI included new variants of medicines Sitagliptin and its combination in its all Jan Aushdhi Kendras.

    Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. All these variants are available at 60% to 70% lesser prices than branded variants.

  • Pfizer and Flynn pharma fined 70 mn pound by UK

    Competition and Markets Authority (CMA) found that Pfizer and Flynn charged unfairly high prices for phenytoin sodium capsules for over 4 years, ultimately paid for by the NHS. These two companies are fined for 70 mn pound out of which Pfizer fined pound 63 million and Flynn fined for pound 6.7 million.

  • Many anticancer and other medicines to get affordable in the country

    Many anticancer ​and several other medicines are getting cheaper after their inclusion in the National List of Essential Medicines (NLEM) 2022 by the Government of India. The medicines in NLEM should be available at affordable costs fixed by National Pharmaceutical Pricing Authority and with assured quality.

  • IPC to add 8 chemical monographs and 7 Veterinary Monograph

    Indian Pharmacopoeia commission (IPC) to add 8 chemical monographs and 7 Veterinary Monographs and open them for Public Review and Comments.

    IPC to add chemical monographs which include, Aceclofenac and paracetamol Tablets, Azacitidine for Injection, Ethamsylate, Lactulose Solution, Atropine Ophthalmic solution, Moxifloxacin Tablets, Remogliflozin Etabonate and Remogliflozin Tablets.

  • First intra nasal COVID-19 vaccine approved in India

    ​​CDSCO has approved a recombinant nasal vaccine for COVID-19 for restricted use in emergency situations.It is a recombinant replication deficient adenovirus vectored vaccine with a prefusion stabilised spike protein.

    Dr Mansukh Mandaviya Minister of Health and Family Welfare informed today that Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by CDSCO for primary immunization against COVID-19 in 18 plus age group for restricted use in emergency situation.

  • Inflation reduction act will cut Healthcare costs in USA

    ​With inflation reduction act, Medicare finally having the power to negotiate prescription drug prices with pharmaceutical industries which will affect millions of Americans across all 50 states and the District of Columbia

    It will lead to prescription drug costs capped at USD 2,000 annually in Medicare, and will save hundreds of dollars per year on health insurance premiums because of the law.

  • Centre approves of three more Bulk Drug Parks

    The Department of Pharmaceuticals has conveyed in-principle approval to the proposals of the three States Viz, Himachal Pradesh, Gujarat and Andhra Pradesh under the Scheme for Promotion of Bulk Drug Parks, a key initiative to support the Bulk Drugs manufacturing in the country.

  • Indian pharma market bloomed 12.1 percent in August

    ​​​​The overall Indian pharmaceutical market grown around 12.1 percent by value and 4.8 percent by volume in month of August as per the market research firm AWACS.

    Almost all the therapy areas have shown a robust double-digit growth or in case of units the growth may be single digit due to NLEM permission to hike price come into the picture and number of companies have shown a good price driven growth for the month of August.

  • No more free COVID-19 vaccines in USA, foreseeing full commercialization

    From 2023, there will be no free COVID-19 vaccines for Americans. The US federal government may opt for full commercialization of COVID-19 vaccines and other oral antiviral medicines.

    The US federal government has played the central coordinating role in buying, distributing, and ensuring equitable access to COVID-19 vaccines, therapeutics, and tests.

Subscribe to Government News

Search this website